Cutaneous squamous cell carcinoma manifests as a malignant growth originating from the epidermal keratinocytes and accounts for a significant clinical challenge given its propensity to evolve into aggressive and therapy-resistant disease stages. While many cSCC cases remain manageable through conventional treatments, a subset of tumors undergo a phenotypic transition that endows them with enhanced motility and invasiveness. This transition, known as epithelial-to-mesenchymal transition (EMT), marks the shift from well-differentiated, structured epithelial cells into delocalized, mesenchymal-like cells capable of systemic dissemination. The molecular events governing this transition have remained incompletely characterized until now.

The research spearheaded by Prof. Rami I. Aqeilan and colleagues reveals that WWOX, a protein previously implicated in various tumor suppressive functions, operates as a critical guardian of epidermal identity. WWOX achieves this by stabilizing p63, a master transcription factor pivotal for maintaining epithelial cell differentiation and structural integrity. Through an intricate molecular interplay, WWOX prevents the degradation of p63, thereby preserving the genetic programs essential for keratinocyte specialization and restraining cellular plasticity.

Using an integrative approach combining genetically engineered mouse models and detailed analysis of human tissue specimens, the team demonstrated that abrogation of WWOX expression precipitates a precipitous decline in p63 levels. This destabilization effectively dismantles the safeguard mechanisms that uphold cellular identity, setting the stage for EMT induction. The resulting phenotypic fluidity enables cancer cells to shed their adhesive properties, acquire migratory traits, and penetrate systemic circulation paths, ultimately facilitating metastatic colonization, particularly in vital organs like the lungs.

Further compounding the oncogenic threat, the simultaneous loss of WWOX and the well-characterized tumor suppressor p53 was shown to accelerate tumor development dramatically. Experimental models deficient in both guardians exhibited earlier tumor onset and an escalated degree of malignancy characterized by poor differentiation and heightened invasiveness compared to controls retaining functional WWOX. These findings articulate a synergistic model whereby the concurrent impairment of multiple tumor suppressive pathways drives rapid cSCC progression.

Importantly, the translational significance of this research is underscored by investigations into human clinical samples. Through tissue microarray analyses, a consistent pattern emerged demonstrating that as cSCC advances, both WWOX and p63 protein levels diminish progressively. This correlation not only reinforces the biological importance of the WWOX-p63 axis in restraining tumor aggression but also positions these proteins as valuable prognostic biomarkers. Monitoring their expression profiles could empower clinicians to predict tumor behavior more accurately and tailor therapeutic strategies accordingly.

The implications extend into therapeutic innovation, proposing the restoration or mimicking of WWOX function as a promising intervention against aggressive cSCC. Strategies aimed at bolstering WWOX expression or enhancing p63 stability could reinforce epithelial identity and prevent the EMT process, thereby curtailing metastatic spread. This novel molecular target offers an attractive avenue for drug development efforts seeking to improve outcomes for patients afflicted with advanced skin cancers.

On a molecular level, the binding interaction between WWOX and p63 appears to be essential in preserving p63’s nuclear localization and its transcriptional activity. Loss of WWOX disrupts this complex, rendering p63 vulnerable to proteasomal degradation. This mechanistic insight provides a valuable foundation for exploring small molecules or biologics that could stabilize the WWOX-p63 interaction, representing a refined, mechanism-based therapeutic modality.

The broader context of this study situates WWOX as a pivotal component of the skin’s intrinsic tumor suppressive architecture. It exemplifies the concept that cellular identity and differentiation status are not static traits but active states maintained by molecular sentinels. The failure of these sentinels unleashes a cascade of deleterious cellular reprogramming events that fuel malignancy. Such advances reveal an evolving paradigm in oncology focusing on targeting cellular plasticity as a strategy to impede cancer progression.

Prof. Aqeilan’s pioneering work not only enriches our fundamental understanding of skin cancer biology but also lays a robust framework for future clinical applications. By integrating molecular pathology, genetic modeling, and clinical specimen analyses, it bridges the gap between bench research and patient care. This multi-disciplinary approach exemplifies how deep mechanistic insights into tumor suppressor networks can translate into actionable clinical knowledge.

As cSCC incidence rises globally due to environmental and demographic factors, the urgency for novel diagnostic and therapeutic tools escalates. This study’s identification of the WWOX-p63 axis as a central regulator of tumor behavior represents a significant leap toward meeting this need. It opens exciting new directions to explore the mechanobiology of tumor differentiation states and offers a platform to design next-generation therapies aimed at reinstating the cellular programming necessary to constrain malignancy.

In conclusion, the discovery of WWOX’s critical role in maintaining epidermal identity and suppressing EMT in skin cancer illuminates a novel molecular safeguard against tumor aggressiveness and metastasis. By stabilizing p63, WWOX fortifies the cellular differentiation landscape, preventing the dangerous transformation of skin cells into invasive cancer progenitors. This foundational knowledge promises to reshape clinical approaches to cSCC, offering hope for improved prognostication, personalized treatment regimens, and ultimately better patient outcomes.

Subject of Research: Cells
Article Title: WWOX Maintains Epidermal Identity and Suppresses EMT to Prevent Aggressive Cutaneous Squamous Cell Carcinoma
News Publication Date: 15-Apr-2026
Web References: DOI: 10.1073/pnas.2534844123
References: Proceedings of the National Academy of Sciences
Image Credits: Tirza Bidnay-Mizrahi
Keywords: Skin cancer, Carcinoma, Cancer, Metastasis, Carcinogenesis

Intestinal-type gastric cancer, a predominant histological variant of stomach malignancies, has long challenged oncologists due to its heterogeneous molecular profile and relatively poor prognosis. Among the known markers, the cell surface glycoprotein CD44 has garnered attention not only as a cancer stem cell marker but also due to its association with tumor aggressiveness, metastasis, and resistance to conventional therapies. Nonetheless, the metabolic underpinnings correlating with CD44 expression in this cancer subtype remained poorly defined until this landmark study offered compelling evidence implicating the one-carbon metabolic pathway as a cornerstone molecular feature.

The one-carbon metabolism cascade encompasses a series of enzymatic reactions crucial for nucleotide biosynthesis, methylation reactions, and redox homeostasis—metabolic processes fundamentally necessary for rapid cell proliferation and genomic fidelity. By integrating transcriptomic and metabolomic analyses, the researchers revealed that CD44-positive intestinal-type gastric cancers exhibit a robust upregulation of key enzymes involved in this pathway, including serine hydroxymethyltransferase (SHMT), methylenetetrahydrofolate dehydrogenase (MTHFD), and thymidylate synthase (TYMS). This enhanced metabolic flux suggests a tailored biochemical reprogramming facilitating the proliferative and survival advantage observed in these cancer cells.

Notably, the study utilized clinical tumor specimens alongside in vitro gastric cancer cell models to validate the observed molecular signatures. High-throughput gene expression profiling demonstrated a consistent correlation between CD44 positivity and elevated one-carbon metabolism gene expression networks. Metabolic flux assays further corroborated these findings, showing increased folate-mediated one-carbon unit transfer rates—a biochemical hallmark indicating an amplified anabolic state that supports nucleotide synthesis and epigenetic modifications critical for malignant transformation and progression.

The implications of this metabolic signature are profound. By harnessing advanced CRISPR-Cas9 gene editing and pharmacologic inhibition of select one-carbon enzymes, the authors experimentally diminished CD44-positive gastric cancer cell viability and tumorigenicity in xenograft mouse models. These manipulations led to cell cycle arrest, increased apoptosis, and compromised DNA repair mechanisms, underscoring one-carbon metabolism’s pivotal role in maintaining malignant phenotypes within this cancer subset. Such findings propel the one-carbon pathway as an attractive therapeutic target, championing a shift toward metabolism-centric precision oncology.

Further dissection of molecular interactions unveiled epigenetic modifications driven by methyl group donors generated through one-carbon flux as a potential mechanism reinforcing CD44 expression itself, suggesting a possible feedback loop sustaining stemness and oncogenicity. This bidirectional relationship between metabolism and gene regulation adds an additional layer of complexity to cancer biology, wherein metabolic circuits intertwine with transcriptional programs and epigenetic landscapes to dictate tumor behavior and heterogeneity.

Clinically, these discoveries bear significant promise for the development of diagnostic biomarkers. Liquid biopsy approaches detecting metabolic enzyme transcripts or circulating metabolites linked to the one-carbon pathway could serve as minimally invasive indicators predicting CD44 status and disease aggressiveness. Such advances would facilitate early identification of high-risk patients and real-time monitoring of therapeutic responses, advancing personalized medicine paradigms.

One-carbon metabolism inhibitors have previously been explored in other cancer contexts, yet this research provides the first compelling rationale to prioritize these agents specifically for CD44-positive intestinal-type gastric cancer. Drugs like methotrexate and pemetrexed, classical antifolates targeting this metabolic axis, might be repurposed or optimized to exploit the metabolic dependencies uncovered by Joo et al., potentially enhancing clinical outcomes in a patient population that often exhibits resistance to conventional chemotherapy.

The study’s comprehensive methodological approach—combining omics analyses, functional genomics, and preclinical models—offers an exemplary framework illustrating how dissecting cancer metabolism at the molecular circuitry level unravels novel vulnerabilities. This strategy not only deepens fundamental understanding but also charts a translational course for bringing laboratory insights to bedside application, accelerating the pipeline of innovative therapeutics.

Moreover, this research highlights the broader relevance of metabolic pathways in defining cancer subtypes beyond mere genetic mutations, advocating increased incorporation of metabolic phenotyping in future oncologic classification systems. Such integrative taxonomy would refine prognostic stratification and foster development of metabolism-informed therapeutic regimens tailored to specific tumor metabolic profiles.

While promising, the authors acknowledge limitations including the need for larger cohort validations and exploration of potential metabolic crosstalk with other tumor microenvironment components such as immune cells and stromal elements. Future investigations may also examine resistance mechanisms arising from metabolic plasticity and compensatory pathways, as well as combinatorial strategies integrating metabolic inhibitors with immunotherapy or targeted agents.

This discovery of the one-carbon metabolic pathway as a molecular hallmark of CD44-positive intestinal-type gastric cancer opens an exciting frontier. By illuminating how altered metabolism intertwines with cellular phenotypes fundamental to cancer aggressiveness, this work sets the stage for innovative therapeutic designs centered on disrupting cancer cell metabolic networks. It represents a crucial step towards metabolic precision oncology tailored to the molecular identities of gastric tumor subtypes.

With gastric cancer representing a significant global health burden and survival rates stagnating, breakthroughs such as these offer hope of translating molecular understanding into meaningful clinical benefit. As research continues to elucidate metabolism’s multifaceted roles in tumor biology, integrating such insights promises to transform gastric cancer management through targeted interventions exploiting tumor-specific metabolic dependencies.

In summary, the identification of the one-carbon metabolic pathway as a novel molecular signature for CD44-expressing intestinal-type gastric cancer reframes our understanding of tumor biology and revitalizes metabolic targeting as a cornerstone of future therapeutic strategies. The study by Joo and colleagues is not merely a significant academic advance but a clarion call to the cancer research community to harness metabolism in the ongoing quest to ameliorate lethal malignancies through science-driven precision medicine.

Subject of Research: Molecular and metabolic characterization of CD44-positive intestinal-type gastric cancer with emphasis on the one-carbon metabolic pathway.

Article Title: One-carbon metabolic pathway is a novel molecular signature for CD44-positive intestinal-type gastric cancer.

Article References:
Joo, S., Bae, Y., Yoon, B.K. et al. One-carbon metabolic pathway is a novel molecular signature for CD44-positive intestinal-type gastric cancer. Cell Death Discov. 11, 399 (2025). https://doi.org/10.1038/s41420-025-02704-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02704-5